Drugs / Vx-006
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02289196 | Mar → Oct 2014 | neoplasm | Vaxon Biotech | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vx-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02289196 ↗ |
| Modality | Vaccine | “Vx-006 Vaccine” NCT02289196 ↗ |
| Route | Other | “Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks” NCT02289196 ↗ |